Phase 2 trial of IV efgartigimod for the treatment of primary Primary Sjögren’s Syndrome Program: Efgartigimod
ARGX-117
Multifocal Motor Neuropathy (MMN)
ARGX-117
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy Program: ARGX-117